Eric Huang, Ph.D. is founder and CEO of COINX Ventures, a bay area venture capital company with an accelerator program focusing on grow-stage companies. Prior to that, he was a Managing Director of Arch Equity Holdings, concentrating in biotechnology, medical devices, electronics, mobile, social network, and technology innovation. Eric Huang was also formerly the CEO and Vice Chairman of the Yangtze Acquisition Corporation, a special purpose acquisition corporation under American Stock Exchange.
Prior to that, Eric was founder and Managing Director of Sinotek Ventures which was one of the earliest biotechnology venture funds in Taiwan. Eric Huang was also a founding member of Uni-Pac Venture Capital Firm, a subsidiary of Taiwan Cellular Group.
Throughout his career, Mr. Huang has helped organize and finance numerous companies including, but not limited to, AnaSpec (acquired by Euogentec), Genassiance Pharmaceuticals (GNSC, acquired by Clinical Data), Orchid Biosciences (ORCH), OmniVision (OVTI), AbGenomics (founding board director), Alpha-Top Corp (acquired by ECS), Arima (TWSE:2381), and so on. In 2003, Mr. Huang assisted in Jintex Corporation for management buyout (MBO) of 40% equity from Protex International, the largest player in speciality chemicals in France, and brought Jintex public in 2005.
Mr. Huang holds a M.S. and Ph.D. from Cornell University and China University of Political Science and Law (CUPL), and completed Executive program at Harvard Business School. Mr. Huang is also a co-author of “Security Law- Principal, Practice and Cases” (Law Press China, 2007). He also served as Visiting Professor at Jinan University in China, and Chief Advisor of international affairs and exchanges for National United University in Taiwan.
Mr. Huang is now a board director of Monte Jade West Association and Vice President of Silicon Valley Chinese American Computer and Commerce Association.